TITLE

Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency

AUTHOR(S)
Carratù, Pierluigi; Spicuzza, Lucia; Cassano, Anna; Maniscalco, Mauro; Gadaleta, Felice; Lacedonia, Donato; Scoditti, Cristina; Boniello, Ester; Di Maria, Giuseppe; Resta, Onofrio
PUB. DATE
January 2009
SOURCE
Orphanet Journal of Rare Diseases;2009, Vol. 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, which rapidly leads to chronic respiratory failure requiring mechanical ventilation. Currently, forced vital capacity (FVC) < 50% is considered as physiologic marker for admitting patients to Noninvasive Positive Pressure Ventilation (NPPV) intervention, although it has been recently shown the median survival of patients with baseline FVC < 75% much shorter than median survival of patients with baseline FVC > 75%, independently by any treatment. Aim: To assess the role of NPPV in improving outcome of ALS, a retrospective analysis was performed to investigate 1 year survival of ALS patients with FVC < 75% and nocturnal respiratory insufficiency, treated with NPPV, compared to a well-matched population of ALS patients, who refused or was intolerant to NPPV. Methods: We investigated seventy-two consecutive ALS patients who underwent pulmonary function test. Forty-four presented a FVC > 75% and served as control group. Twenty-eight patients presented a FVC < 75% and showed, at polysomnography analysis, nocturnal respiratory insufficiency, requiring NPPV; sixteen were treated with NPPV, while twelve refused or were intolerant. Results: Increased survival rate at 1 year in patients with FVC < 75% treated with NPPV, as compared to those who refused or could not tolerate NPPV (p = 0.02), was observed. The median rate of decline in FVC% was slower in NPPV patients than in patients who did not use NPPV (95% CI: 0.72 to 1.85; p < 0.0001). Conclusion: This report demonstrates that early treatment with NPPV prolongs survival and reduces decline of FVC% in ALS.
ACCESSION #
42094984

 

Related Articles

  • Amyotrophic lateral sclerosis is not linked to multiple sclerosis in a population based study. van Doormaal, Perry T.; Gallo, Alessandro; van Rheenen, Wouter; Veldink, Jan H.; van Es, Michael A.; van den Berg, Leonard H. // Journal of Neurology, Neurosurgery & Psychiatry;Aug2013, Vol. 84 Issue 8, p940 

    The article focuses on the connection between amyotrophic lateral sclerosis (ALS) which is a progressive neurodegenerative disease and multiple sclerosis (MS) which is a progressive inflammatory disorder of the central nervous system. It mentions that ALS was characterized by progressive...

  • Suxamethonium chloride.  // Reactions Weekly;7/23/2011, Issue 1361, p38 

    The article describes the case of a female patient with undiagnosed amyotrophic lateral sclerosis who developed catastrophic hyperkalaemia following administration of suxamethonium chloride for respiratory insufficiency, published in the June 2011 issue of "Clinical Medicine."

  • Non-invasive ventilation.  // Thorax;Dec2006 Supplement 2, Vol. 61, pii52 

    The article presents abstracts of several studies on non-invasive ventilation in obstructive pulmonary disease patients. They include "Audit of Chronic Obstructive Pulmonary Disease Patients With Acute Type II Respiratory Failure: Are We Giving Them A Chance?," "Respiratory Function and Survival...

  • Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective. Fernandes, Stephanie A.; Douglas, Andrew G. L.; Varela, Miguel A.; Wood, Matthew J. A.; Yoshitsugu Aoki // Journal of Nucleic Acids;2013, p1 

    Amyotrophic lateral sclerosis (ALS) is a progressive and lethal disease of motor neuron degeneration, leading to paralysis of voluntary muscles and death by respiratory failure within five years of onset. Frontotemporal dementia (FTD) is characterised by degeneration of frontal and temporal...

  • Pulmonary function tests in patients with amyotrophic lateral sclerosis and the association between these tests and survival. Mousavi, Seyed-Ali Javad; Zamani, Babak; Shahmiri, Shahab Shahabi; Rohani, Mohammad; Ali Shahidi, Gholam; Mostafapour, Elyas; Hemasian, Helia; Raji, Hanieh // Iranian Journal of Neurology;2014, Vol. 13 Issue 3, p131 

    Background: The rapidity of progression of amyotrophic lateral sclerosis (ALS) to death or respiratory failure impacts patients, clinicians, and clinical investigators. The aim of this study is to evaluate of the pulmonary function tests (PFTs) in patients with ALS and the association between...

  • Genetic inroads in familial ALS. Shaw, Pamela J. // Nature Genetics;Oct2001, Vol. 29 Issue 2, p103 

    Amyotrophic lateral sclerosis (ALS) is a common neurodegenerative disease causing cell death of motor neurons and progressive muscle weakness. The disease is familial in ten percent of cases, of which one-fifth are due to mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1). Two...

  • Erratum to: ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis.  // Molecular Neurodegeneration;2/8/2016, Vol. 11, p1 

    A correction to the article "ADAMTS-4 Promotes Neurodegenerative in a Mouse Model of Amyotrophic Lateral Sclerosis" that was published in the 2016 issue is presented.

  • Motor neurone disease. K. Talbot // Postgraduate Medical Journal;Sep2002, Vol. 78 Issue 923, p513 

    Motor neurone disease (MND), or amyotrophic lateral sclerosis (ALS), is a neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. Confirming the diagnosis may initially be difficult until the...

  • TDP-43 Is Not a Common Cause of Sporadic Amyotrophic Lateral Sclerosis. Guerreiro, Rita J.; Schymick, Jennifer C.; Crews, Cynthia; Singleton, Andrew; Hardy, John; Traynor, Bryan J. // PLoS ONE;2008, Vol. 3 Issue 6, p1 

    Background: TAR DNA binding protein, encoded by TARDBP, was shown to be a central component of ubiquitin-positive, tau-negative inclusions in frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Recently, mutations in TARDBP have been linked to familial and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics